Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation

BioDrugs

Volumn 22, Issue 4, 2008, Pages 223-237

  Woitiski, Camile B ^a   Carvalho, Rui A ^b   Ribeiro, António J ^a   Neufeld, Ronald J ^c   Veiga, Francisco ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Drug delivery systems; Insulin, general; Nanoparticles

Indexed keywords

CHITOSAN; EUDRAGIT RS; INSULIN; LIGAND; NANOPARTICLE; POLYGLACTIN; POLYMER; PROTEINASE INHIBITOR;

DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; GASTROINTESTINAL ABSORPTION; HUMAN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; INSULIN; INTESTINAL ABSORPTION; NANOPARTICLES;

EID: 47049095564     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822040-00002     Document Type: Review

References (140)

1. Frokjaer S, Otzen DD. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005; 4: 298-306
2. Cournarie F, Auchere D, Chevenne D, et al. Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats. Int J Pharm 2002; 242 (1-2): 325-8
3. Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 2007; 117 (2): 163-70
4. Still JG. Development of oral insulin: progress and current status. Diabetes Metab Res Rev 2002; 18 Suppl. 1: S29-37
5. Agarwal V, Khan MA. Current status of the oral delivery of insulin. Pharmaceutical Technology 2001 Oct: 76-90
6. Crane CW, Path MC, Luntz GRWN. Absorption of insulin from the human small intestine. Diabetes 1968; 17: 625-7
7. Ghilzai NMK. New developments in insulin delivery. Drug Dev Ind Pharm 2003; 29 (3): 253-65
8. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005; 19 (3): 165-77
9. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006; 11 (19/20): 905-10
10. Morishita M, Goto T, Peppas NA, et al. Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption. J Control Release 2004; 97 (1): 115-24
11. Cunha AS, Grossiordo JL, Puisieux F, et al. Insulin in w/o/w multiple emulsion: preparation, characterization and determination of stability towards proteases in vitro. J Microencapsul 1997; 14: 311-9
12. Matsuzawa A, Morishita M, Takayama K, et al. Absorption of insulin using water-in-oil-in-water emulsion from enteral loop in rats. Biol Pharm Bull 1995; 18: 1718-23
13. Fukunaga M, Miller MM, Deftos LJ. Liposome-entrapped calcitonin and parathyroid hormone are orally effective in rats. Horm Metab Res 1991; 23: 166-7
14. Allemann E, Leroux J-C, Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 1998; 34 (2-3): 171-89
15. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev 1993; 10: 141-62
16. Morishita I, Morishita M, Takayama K, et al. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int J Pharm 1992; 78: 9-16
17. Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm 1995; (41): 2-13
18. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55 (3): 329-47
19. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 2006; 97 (6): 1184-90
20. Reis CP, Ribeiro AJ, Houng S, et al. Nanoparticulate delivery system for insulin: design, characterization and in vitro/in vivo bioactivity. Eur J Pharm Sci 2007; 30 (5): 392-7
21. Ziv E, Bendayan M. Intestinal absorption of peptides through the enterocytes. Microsc Res Tech 2000; 49 (4): 346-52
22. Bendayan M, Ziv E, Ben-Sasson R, et al. Morpho-cytochemical and biochemical evidence for insulin absorption by the rat ileal epithelium. Diabetologia 1990; 33 (4): 197-204
23. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004; 12 (2): 65-70
24. Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 2004; 1 (1): 141-63
25. Hazzard RA, Hodges GM, Scott JD, et al. Early intestinal microparticle uptake in the rat. J Anat 1996; 189 (2): 265-71
26. Jung T, Kamm W, Breitenbach A, et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000; 50 (1): 147-60
27. Reis CP, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2006; 2 (2): 53-65
28. TenHoor C, Dressman J. Oral absorption of peptides and proteins. S T P Pharma Sci 1992; 2: 301-12
29. Langguth P, Bohner V, Heizmann J, et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release 1997; 46 (1-2): 39-57
30. Schilling RJ, Mitra AK. Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm Res 1991; 8 (6): 721-7
31. Chang L-L, Stout LE, Wong WD, et al. Immunohistochemical localization of insulin-degrading enzyme along the rat intestine, in the human colon adenocarcinoma cell line (Caco-2), and in human ileum. J Pharm Sci 1997; 86 (1): 116-9
32. Drasar B, Hill M. Bacterial glycosidase. In: Drasar BS, Hill MJ, editors. Human intestinal flora. London: Academic Press, 1974: 54-71
33. Sinko PJ, Hu M, Amidon GL. Carrier mediated transport of amino acids, small peptides and their analogs. J Control Release 1987; 6: 115-21
34. Larhed AW, Artursson P, Grasj J. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci 1997; 86 (6): 660-5
35. Gullberg E. Particle transcytosis across the human intestinal epithelium: model development and target identification for improved drug delivery. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Pharmacy 3. Uppsala: Acta Universitatis Upsaliensis, 2005: 1-62 [online]. Available from URL: http://publications.uu.se/abstract.xsql?dbid=4780 [Accessed 2008 May 27]
36. Pauletti GM, Gangwar S, Knipp GT, et al. Structural requirements for intestinal absorption of peptide drugs. J Control Release 1996; 41 (1-2): 3-17
37. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm Res 1996; 13: 1760-4
38. Masaoka Y, Tanaka Y, Kataoka M, et al. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 2006; 29 (3-4): 240-50
39. Zhou XH. Overcoming enzymatic and absorption barriers to nonparenterally administered protein and peptide drugs. J Control Release 1994; 29: 239-52
40. Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release 1994; 29: 253-67
41. Kostarelos K. Rational design and engineering of delivery systems for therapeutics: biomedical exercises in colloid and surface science. Adv Colloid Interface Sci 2003; 106 (1-3): 147-68
42. Liu H, Tang R, Pan WS, et al. Potential utility of various proteases inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol 2003; 55: 1523-9
43. Shao Z, Li Y-P, Chermak T, et al. Cyclodextrins as mucosal absorption promoters of insulin II: effects of beta-cyclodextrins derivatives on alpha-chymotriptic degradation and enteral absorption of insulin in rats. Pharm Res 1994; 11: 1174-9
44. Mesiha M, Ponnapula S, Plakogiannis F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acids and alpha-tocopherol dispersions. Int J Pharm 2002; 249: 1-5
45. Eaimtrakarn S, Rama Prasad YV, Ohno T, et al. Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. J Drug Target 2002; 10: 255-60
46. Morishita M, Kamei N, Ehara J, et al. A novel approach using functional peptides for efficient intestinal absorption of insulin. J Control Release 2007; 118 (2): 177-84
47. Damgé C, Michel C, Aprahamian M, et al. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37: 246-51
48. Damgé C, Vranckx H, Balschmidt P, et al. Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86 (12): 1403-9
49. Radwan MA, Aboul-Enein HY. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul 2002; 19 (2): 225-35
50. Krauland AH, Guggi D, Bernkop-Schnurch A. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats. J Control Release 2004; 95 (3): 547-55
51. Krauland AH, Bernkop-Schnurch A. Thiomers: development and in vitro evaluation of a peroral microparticulate peptide delivery system. Eur J Pharm Biopharm 2004; 57 (2): 181-7
52. Fasano A, Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997; 99 (6): 1158-64
53. Behrens I, Pena AIV, Alonso MJ, et al. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm Res 2002; 19 (8): 1185-93
54. Morishita M, Aoki Y, Sakagami M, et al. In situ ileal absorption of insulin in rats: effects of hyaluronidase pretreatment diminishing the mucous/glycocalyx layers. Pharm Res 2004; 21 (2): 309-16
55. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 2006; 325 (1-2): 147-54
56. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999; 35 (2-3): 249-57
57. Cui F, Shi K, Zhang L, et al. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 2006; 114 (2): 242-50
58. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother 2004; 58 (3): 168-72
59. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater 2002; 6 (4): 319-27
60. Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev 2001; 47 (1): 21-37
61. Sarmento B, Ribeiro A, Veiga F, et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007; 24 (12): 2198-206
62. des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006; 116 (1): 1-27
63. Mohanraj V, Chen Y. Nanoparticles: a review. Trop J Pharm Res 2006; 5 (1): 561-73
64. Hussain N. Ligand-mediated tissue specific drug delivery. Adv Drug Deliv Rev 2000; 43 (2-3): 95-100
65. Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2005; 2 (1): 75-81
66. Russell-Jones GJ. Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium. J Drug Target 2004; 12: 113-23
67. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001; 50 (1-2): 81-106
68. Thomas NW, Jenkins PG, Howard KA, et al. Particle uptake and translocation across epithelial membranes. J Anat 1996; 189: 487-90
69. Florence AT, Hillery AM, Hussain N, et al. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 1995; 36 (1-2): 39-46
70. Zhang N, Ping Q, Huang G, et al. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006; 327 (1-2): 153-9
71. Galindo-Rodriguez SA, Allemann E, Fassi H, et al. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 2005; 22: 419-63
72. Pinto-Alphandary H, Aboubakar M, Jaillard D, et al. Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm Res 2003; 20 (7): 1071-84
73. Pan Y, Li Y-J, Zhao H-Y, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249 (1-2): 139-47
74. Sarmento B, Martins S, Ribeiro A, et al. Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. Int J Pept Res Ther 2006; 12 (2): 131-8
75. Prego C, Garcia M, Torres D, et al. Transmucosal macromolecular drug delivery. J Control Release 2005; 101 (1-3): 151-62
76. Vila A, Sanchez A, Tobio M, et al. Design of biodegradable particles for protein delivery. J Control Release 2002; 78 (1-3): 15-24
77. Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999; 182 (1): 21-32
78. Chen H, Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliv Rev 1998; 34 (2-3): 339-50
79. Foss AC, Peppas NA. Investigation of the cytotoxicity and insulin transport of acrylic-based copolymer protein delivery systems in contact with caco-2 cultures. Eur J Pharm Biopharm 2004; 57 (3): 447-55
80. Gowthamarajan K, Kulkarni GT. Oral insulin: fact or fiction? Possibilities of achieving oral delivery for insulin. Resonance 2003; 8 (5): 38-46
81. Reis CP, Veiga F, Nunes P, et al. Toxicological in vivo studies of an oral insulin nanosystem [letter]. Toxicol Lett 2007; 172 Suppl. 1: S90
82. Moghimi SM, Hedeman H, Muir LS, et al. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochin Biophys Acta 1993; 1157: 233-40
83. Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307 (1): 93-102
84. Binder C, Lauritzen T, Faber O, et al. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-99
85. Daugherty AL, Mrsny RJ. Transcellular uptake mechanisms of intestinal epithelial barrier: part I. Pharm Sci Technol Today 1999; 4: 144-51
86. Kraehenbuhl JP, Neutra MR. Epithelial M cells: differentiation and function. Annu Rev Cell Dev Biol 2000; 16: 301-32
87. Beier R, Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol Gastrointest Liver Physiol 1998 July 1; 275 (1): G130-7
88. Ermak TH, Giannasca PJ. Microparticle targeting to M cells. Adv Drug Deliv Rev 1998; 34 (2-3): 261-83
89. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998; 34 (2-3): 135-54
90. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 2001; 50 (1-2): 107-42
91. Damge C, Michel C, Aprahamian M, et al. Nanocapsules as carriers for oral peptide delivery. J Control Release 1990; 13: 233-9
92. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997; 14 (3): 259-66
93. Sakuma S, Sudo R, Suzuki N, et al. Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. J Control Release 2002; 81 (3): 281-90
94. Aprahamian M, Michel C, Humbert W, et al. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as new drug carrier in the small intestine. Biol Cell 1987; 61: 69-76
95. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990; 11 (1-3): 205-14
96. Michel C, Aprahamian M, Defontaine L, et al. The effect of site of absorption in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharm Pharmacol 1991; 43: 1-5
97. Tirosh B, Rubinstein A. Migration of adhesive and nanoadhesive particles in the rat intestine under altered mucus secretion conditions. J Pharm Sci 1998; 87: 453-6
98. Kamba M, Seta Y, Kusai A, et al. A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. Int J Pharm 2000; 208: 61-70
99. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001; 50 Suppl. 1: S69-89
100. Doyle-McCullough M, Smyth SH, Moyes SM, et al. Factors influencing intestinal microparticle uptake in vivo. Int J Pharm 2007; 335 (1-2): 79-89
101. Dawson GF, Halbert GW. The in vitro cell association of invasin coated polylactide-co-glycolide nanoparticles. Pharm Res 2000; 17: 1420-5
102. Shirui M, Oliver G, Dagmar F, et al. Uptake and transport of PEG-graft-trimethylchitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm Res 2005; 22 (12): 2058-68
103. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol 1989; 146: 59-66
104. Jani PU, Halbert GW, Langridge J, et al. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 1989; 41: 809-12
105. Jani PU, Halbert GW, Langridge J, et al. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990; 42: 821-6
106. Ebel JP. A method for quantifying particle absorption from the small intestine of the mouse. Pharm Res 1990; 7: 848-51
107. Damgé C, Aprahamian M, Marchais H, et al. Intestinal absorption of PLGA microspheres in the rat. J Anat 1996; 189: 491-501
108. Torché AM, Jouan H, Le Corre P, et al. Ex vivo and in situ PLGA microspheres uptake by pig ileal Peyer's patch segment. Int J Pharm 2000; 201: 15-27
109. Blanchette J, Kavimandan N, Peppas NA. Principles of transmucosal delivery of therapeutic agents. Biomed Pharmacother 2004; 58 (3): 142-51
110. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 2006; 58 (1): 15-28
111. Qian F, Cui F, Ding J, et al. Chitosan graft copolymer nanoparticles for oral protein drug delivery: preparation and characterization. Biomacromolecules 2006; 7 (10): 2722-7
112. Smith JM, Dornish M, Wood EJ. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 2005; 26: 3269-76
113. Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions trough protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995; 96: 710-20
114. Smith JM, Wood EJ, Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm Res 2004; 21: 43-39
115. Schipper NGM, Varum KM, Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs I: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res 1996; 13: 1686-92
116. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Exp Opi Drug Deliv 2005; 2: 843-54
117. Camenisch G, Alsenz J, van de Waterbeemd H, et al. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998; 6 (4): 313-9
118. Fasano A. Innovative strategies for the oral delivery of drugs and peptides. Trend Biotechnol 1998; 16 (4): 152-7
119. Swaan PW. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm Res 1988; 15: 826-34
120. Neutra MR, Phillips TL, Mayer EL, et al. Transport of membrane-bound macro-molecule by M cells in follicule associated epithelium of rabbit Peyer's patch. Cell Tissue Res 1987; 247: 537-46
121. Frey A, Giannasca KT, Weltzin R, et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996; 184: 1045-59
122. Owen RL. Sequential uptake of horseradish peroxidase by lymphoid follicule epithelium of Peyer's patches in the normal unobstructed mouse intestine: an ultrastructural study. Gastroenterology 1977; 72: 440-51
123. Jepson MA, Simmons NL, Savidge TC, et al. Selective binding and transcytosis of latex microspheres by rabbit intestinal M cells. Cell Tissue Res 1993; 271: 399-405
124. Ragnarsson E. Effects of microparticle drug delivery systems: tissue responses and transcellular transport. Digital comprehensive summaries of Uppsala dissertations from the Faculty of Pharmacy 25. Uppsala: Acta Universitatis Upsaliensis, 2005: 1-59 [online]. Available from URL: http://publications.uu.se/abstract.xsql?dbid=6260 [Accessed 2008 May 27]
125. Desai MP, Labhasetwar V, Walter E, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13 (12): 1838-45
126. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release 2000; 65 (1-2): 261-9
127. McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable poly-d,l-lactide micro and nanoparticles in intestinal epithelia. Eur J Pharm Sci 1998; 6 (2): 153-63
128. Desai MP, Labhasetwar V, Amidon GL, et al. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14 (11): 1568-73
129. Norris DA, Sinko PJ. Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. J Appl Polym Sci 1997; 63 (11): 1481-92
130. Andrianov AK, Payne LG. Polymeric carriers for oral uptake of microparticulates. Adv Drug Deliv Rev 1998; 34 (2-3): 155-70
131. Couvreur P, Barratt G, Fattal E, et al. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst 2002; 19: 99-134
132. Mathiowitz E, Jacob JS, Jong Eun O, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997; 386: 410-4
133. Delie F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34 (2-3): 221-33
134. Landau BR, Wahren J, Chandramouli V, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996; 98 (2): 378-85
135. Calvo P, Remuñán-Lópes C, Vila-Jato JL, et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polymer Sci 1997; 63 (1): 125-32
136. Perdigoto R, Furtado AL, Porto A, et al. Sources of glucose production in cirrhosis by 2H2O ingestion and 2H NMR analysis of plasma glucose. Biochim Biophys Acta 2003; 1637 (2): 156-63
137. Jin ES, Jones JG, Merritt M, et al. Glucose production, gluconeogenesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic resonance analysis of a single glucose derivative. Ann Biochem 2004; 327 (2): 149-55
138. Jones JG, Carvalho RA, Franco B, et al. Measurement of hepatic glucose output, Krebs cycle, and gluconeogenic fluxes by NMR analysis of a single plasma glucose sample. Ann Biochem 1998; 263 (1): 39-45
139. Carvalho RA, Jones JG, McGuirk C, et al. Hepatic gluconeogenesis and Krebs cycle fluxes in a CCl4 model of acute liver failure. NMR Biomed 2002; 15 (1): 45-51
140. Hazey JW, Yang D, Powers L, et al. tracing gluconeogenesis with deuterated water: measurement of low deuterium enrichments on carbons 6 and 2 of glucose. Ann Biochem 1997; 248 (1): 158-67